GLP-1 and dual-agonist therapy

Molecule

Semaglutide

Class

GLP-1 receptor agonist

Dosing

Once weekly

A once-weekly GLP-1 receptor agonist prescribed for weight management when clinically appropriate. Semaglutide mimics a gut hormone that regulates appetite and slows gastric emptying, which is why most patients report feeling full sooner and longer.

Molecule

Tirzepatide

Class

Dual GIP and GLP-1 receptor agonist

Dosing

Once weekly

Tirzepatide acts on two gut-hormone receptors rather than one — both GIP and GLP-1. That dual mechanism is what distinguishes it from semaglutide, and why it is often described as the next generation of metabolic therapy.

Molecule

Semaglutide

Class

GLP-1 receptor agonist

Dosing

Once weekly

Wegovy is Novo Nordisk's brand of semaglutide for chronic weight management. It now comes in two forms: a once-daily oral tablet — the first oral GLP-1 approved for weight loss — and a once-weekly injection, including a higher-dose 7.2 mg option for people who have already tolerated 2.4 mg.

Molecule

Tirzepatide

Class

Dual GIP and GLP-1 receptor agonist

Dosing

Once weekly

Zepbound is Eli Lilly's brand of tirzepatide labelled for chronic weight management. Same molecule as Mounjaro, approved under a weight-management indication and, more recently, for obstructive sleep apnea in adults with obesity.

Molecule

Tirzepatide

Class

Dual GIP and GLP-1 receptor agonist

Dosing

Once weekly

Mounjaro is Eli Lilly's brand of tirzepatide, labelled for glycemic control in adults with type 2 diabetes. It is the same molecule as Zepbound under a different indication.